Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Phase II, Open Label, Multicenter, Efficacy and Safety Study of 852A Administered Intravenously to Subjects With Unresectable Metastatic Cutaneous Melanoma.

NCT00189332 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00189332
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00189332 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Phase II, Open Label, Multicenter, Efficacy and Safety Study of 852A Administered Intravenously to Subjects With Unresectable Metastatic Cutaneous Melanoma.
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2005
Completion date
August 31, 2006
Enrollment
28
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma, unresectable metatstatic cutaneous melanoma